Global Ancylostomiasis (Hookworm Infections) Trials Review Market Growth & Research Report 2015 Radiant Insights, Inc
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Global</strong> <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) <strong>Trials</strong> <strong>Review</strong><br />
<strong>Market</strong> <strong>Growth</strong> & <strong>Research</strong> <strong>Report</strong> <strong>2015</strong>: <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Summary<br />
<strong>Global</strong>Data's clinical trial report, "<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) <strong>Global</strong> Clinical <strong>Trials</strong><br />
<strong>Review</strong>, H2, <strong>2015</strong>" provides an overview of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) clinical trials<br />
scenario. This report provides top line data relating to the clinical trials on <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong><br />
<strong>Infections</strong>). <strong>Report</strong> includes an overview of trial numbers and their average enrollment in top countries<br />
conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 &<br />
E7), phase, trial status, end points status and sponsor type. <strong>Report</strong> also provides prominent drugs for inprogress<br />
trials (based on number of ongoing trials). <strong>Global</strong> Data Clinical Trial <strong>Report</strong>s are generated<br />
using <strong>Global</strong> Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are<br />
collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.<br />
Clinical trials database undergoes periodic update by dynamic process.<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
The report enhances the decision making capabilities and helps to create an effective counter strategies to<br />
gain competitive advantage.<br />
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of<br />
data for the indicated disease.<br />
Scope<br />
- The report provides a snapshot of the global clinical trials landscape<br />
- <strong>Report</strong> provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status,<br />
Trial Phase, Sponsor Type and End point status<br />
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining<br />
to the company<br />
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason<br />
for unaccomplishment<br />
- The <strong>Report</strong> provides enrollment trends for the past five years<br />
- <strong>Report</strong> provides latest news for the past three months<br />
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of<br />
data for the indicated disease.
Reasons to buy<br />
- Assists in formulating key business strategies with regards to investment<br />
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost<br />
- Provides top level analysis of <strong>Global</strong> Clinical <strong>Trials</strong> <strong>Market</strong> which helps in identifying key business<br />
opportunities<br />
- Supports understanding of trials count and enrollment trends by country in global therapeutics market<br />
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed<br />
and uncompleted (terminated, suspended or withdrawn) trials<br />
- Facilitates clinical trial assessment of the indication on a global, regional and country level<br />
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of<br />
data for the indicated disease.<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 4<br />
List of Figures 5<br />
Introduction 6<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) 6<br />
<strong>Report</strong> Guidance 6<br />
Clinical <strong>Trials</strong> by Region 7<br />
Clinical <strong>Trials</strong> and Average Enrollment by Country 8<br />
Top Countries Contributing to Clinical <strong>Trials</strong> in Asia-Pacific 10<br />
Top Countries Contributing to Clinical <strong>Trials</strong> in Europe 11<br />
Top Countries Contributing to Clinical <strong>Trials</strong> in North America 12<br />
Top Five Countries Contributing to Clinical <strong>Trials</strong> in Middle East and Africa 13<br />
Top Countries Contributing to Clinical <strong>Trials</strong> in Central and South America 14
Clinical <strong>Trials</strong> by G7 Countries: Proportion of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) to Infectious<br />
Disease Clinical <strong>Trials</strong> 15<br />
Clinical <strong>Trials</strong> by Phase in G7 Countries 16<br />
Clinical <strong>Trials</strong> in G7 Countries by Trial Status 17<br />
Clinical <strong>Trials</strong> by E7 Countries: Proportion of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) to Infectious<br />
Disease Clinical <strong>Trials</strong> 18<br />
Clinical <strong>Trials</strong> by Phase in E7 Countries 19<br />
Clinical <strong>Trials</strong> in E7 Countries by Trial Status 20<br />
Clinical <strong>Trials</strong> by Phase 21<br />
In Progress <strong>Trials</strong> by Phase 22<br />
Clinical <strong>Trials</strong> by Trial Status 23<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
Clinical <strong>Trials</strong> by End Point Status 24<br />
Unaccomplished <strong>Trials</strong> of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) 25<br />
Subjects Recruited Over a Period of Time 26<br />
Clinical <strong>Trials</strong> by Sponsor Type 27<br />
Prominent Sponsors 28<br />
Prominent Drugs 29<br />
Clinical Trial Profiles 30<br />
Clinical Trial Overview of Top Companies 30<br />
iBio, <strong>Inc</strong>. 30<br />
Clinical Trial Overview of iBio, <strong>Inc</strong>. 30<br />
Clinical Trial Overview of Top Institutes / Government 31<br />
Albert B. Sabin Vaccine Institute, <strong>Inc</strong>. 31<br />
Clinical Trial Overview of Albert B. Sabin Vaccine Institute, <strong>Inc</strong>. 31<br />
Swiss Tropical and Public Health Institute 32
Clinical Trial Overview of Swiss Tropical and Public Health Institute 32<br />
Centers for Disease Control and Prevention 33<br />
Clinical Trial Overview of Centers for Disease Control and Prevention 33<br />
Christian Medical College, Vellore 34<br />
Clinical Trial Overview of Christian Medical College, Vellore 34<br />
Ivo de Carneri Foundation 35<br />
Clinical Trial Overview of Ivo de Carneri Foundation 35<br />
Medicor Foundation 36<br />
Clinical Trial Overview of Medicor Foundation 36<br />
Queensland Children's Medical <strong>Research</strong> Institute 37<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
Clinical Trial Overview of Queensland Children's Medical <strong>Research</strong> Institute 37<br />
Swiss Federal Institute of Technology 38<br />
Clinical Trial Overview of Swiss Federal Institute of Technology 38<br />
Swiss National Science Foundation 39<br />
Clinical Trial Overview of Swiss National Science Foundation 39<br />
The German Society for International Cooperation 40<br />
Clinical Trial Overview of The German Society for International Cooperation 40<br />
Five Key Clinical Profiles 41<br />
Appendix 71<br />
Abbreviations 71<br />
Definitions 71<br />
<strong>Research</strong> Methodology 72<br />
Secondary <strong>Research</strong> 72<br />
About <strong>Global</strong>Data 73
Contact Us 73<br />
Disclaimer 73<br />
Source 74<br />
List of Tables<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> by Region, <strong>2015</strong>* 7<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> and Average Enrollment<br />
by Top Countries, <strong>2015</strong>* 8<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> In Progress by Top<br />
Countries, <strong>2015</strong>* 9<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Asia-Pacific, Top Countries, <strong>2015</strong>*<br />
10<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Europe, Top Countries, <strong>2015</strong>* 11<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, North America, Top Countries,<br />
<strong>2015</strong>* 12<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Middle East and Africa, Top Five<br />
Countries, <strong>2015</strong>* 13<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Central and South America, Top<br />
Countries, <strong>2015</strong>* 14<br />
Proportion of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) to Infectious Disease Clinical <strong>Trials</strong>, G7 Countries<br />
(%), <strong>2015</strong>* 15<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, G7 Countries, Clinical <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, G7 Countries, Clinical <strong>Trials</strong> by Trial Status,<br />
<strong>2015</strong>* 17<br />
Proportion of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) to Infectious Disease Clinical <strong>Trials</strong>, E7 Countries<br />
(%), <strong>2015</strong>* 18<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, E7 Countries, Clinical <strong>Trials</strong> by Phase, <strong>2015</strong>* 19
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, E7 Countries, Clinical <strong>Trials</strong> by Tr ial Status,<br />
<strong>2015</strong>* 20<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> by Phase, <strong>2015</strong>* 21<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> In Progress by Phase<br />
<strong>2015</strong>* 22<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 23<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>*<br />
24<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Terminated Clinical <strong>Trials</strong>, <strong>2015</strong>* 25<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target<br />
Trends, 2010-2014 26<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by Sponsor Type,<br />
<strong>2015</strong>* 27<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 28<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, <strong>Global</strong>, Ongoing Clinical <strong>Trials</strong> by<br />
Prominent Drugs, <strong>2015</strong>* 29<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
iBio, <strong>Inc</strong>., <strong>2015</strong>* 30<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Albert B. Sabin Vaccine Institute, <strong>Inc</strong>., <strong>2015</strong>* 31<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Swiss Tropical and Public Health Institute, <strong>2015</strong>* 32<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Centers for Disease Control and Prevention, <strong>2015</strong>* 33<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Christian Medical College, Vellore, <strong>2015</strong>* 34<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Ivo de Carneri Foundation, <strong>2015</strong>* 35
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Medicor Foundation, <strong>2015</strong>* 36<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Queensland Children's Medical <strong>Research</strong> Institute, <strong>2015</strong>* 37<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Swiss Federal Institute of Technology, <strong>2015</strong>* 38<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
Swiss National Science Foundation, <strong>2015</strong>* 39<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, Clinical <strong>Trials</strong> by<br />
The German Society for International Cooperation, <strong>2015</strong>* 40<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
List of Figures<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> by Region (%), <strong>2015</strong>* 7<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> and Average Enrollment<br />
by Top Countries, <strong>2015</strong>* 8<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> In Progress by Top<br />
Countries, <strong>2015</strong>* 9<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Asia-Pacific, Top Countries (%),<br />
<strong>2015</strong>* 10<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Europe, Top Countries (%), <strong>2015</strong>*<br />
11<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Middle East and Africa, Top Five<br />
Countries (%), <strong>2015</strong>* 13<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics Clinical <strong>Trials</strong>, Central and South America, Top<br />
Countries (%), <strong>2015</strong>* 14<br />
Proportion of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) to Infectious Disease Clinical <strong>Trials</strong>, G7 Countries<br />
(%), <strong>2015</strong>* 15<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, G7 Countries, Clinical <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, G7 Countries, Clinical <strong>Trials</strong> by Trial Status,<br />
<strong>2015</strong>* 17
Proportion of <strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) to Infectious Disease Clinical <strong>Trials</strong>, E7 Countries<br />
(%), <strong>2015</strong>* 18<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, E7 Countries, Clinical <strong>Trials</strong> by Phase, <strong>2015</strong>* 19<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, E7 Countries, Clinical <strong>Trials</strong> by Trial Status,<br />
<strong>2015</strong>* 20<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> by Phase (%), <strong>2015</strong>* 21<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> In Progress by Phase,<br />
<strong>2015</strong>* 22<br />
<strong>Ancylostomiasis</strong> (<strong>Hookworm</strong> <strong>Infections</strong>) Therapeutics, <strong>Global</strong>, Clinical <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 23<br />
Read Complete <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/ancylostomiasishookworm-infections-global-clinical-trials-review-h2-<strong>2015</strong><br />
About <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />
intelligence requirements. We assist and facilitate organizations and individuals procure market research<br />
reports, helping them in the decision making process. We have a comprehensive collection of reports,<br />
covering over 40 key industries and a host of micro markets. In addition to over extensive database of<br />
reports, our experienced research coordinators also offer a host of ancillary services such as, research<br />
partnerships/ tie-ups and customized research solutions.<br />
For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />
Contact:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Blog URL: http://www.radiantinsightsinc.blogspot.com
Change language